Diltiazem improves resuscitation from experimental ventricular fibrillation in dogs

Edmund V. Capparelli(University of California San Diego), Moses S.S. Chow(Hartford Hospital), Arnold Fieldman(Hartford Hospital), Jeffrey Kluger(Hartford Hospital), David M. DiPersio(Hartford Hospital), James Hanyok(Daiichi Sankyo (United States))

Critical Care Medicine

August 1, 1992

10.1097/00003246-199208000-00013

Cited by 2

Related Papers

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

|New England Journal of Medicine|2013|5.2k

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)

|American Heart Journal|2010|482

Effect of ACAT Inhibition on the Progression of Coronary Atherosclerosis

|New England Journal of Medicine|2006|397

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial

|The Lancet|2023|390

Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled study

|American Heart Journal|1995|121